Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
MannKind Corporation
MNKD
$5.94
Name : MannKind Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,823,997,440.00
EPSttm : 0.1
finviz dynamic chart for MNKD
MannKind Corporation
$5.94
2.24%
$0.13

Float Short %

7.41

Margin Of Safety %

-15

Put/Call OI Ratio

0.16

EPS Next Q Diff

0.04

EPS Last/This Y

0.09

EPS This/Next Y

-0.05

Price

5.95

Target Price

9.61

Analyst Recom

1

Performance Q

10.41

Relative Volume

0.85

Beta

0.81

Ticker: MNKD




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13MNKD5.080.190.0378067
2025-11-14MNKD5.070.190.0378508
2025-11-17MNKD4.970.190.1578118
2025-11-18MNKD5.050.190.0778204
2025-11-19MNKD50.190.4778064
2025-11-20MNKD4.960.190.9778077
2025-11-21MNKD5.040.190.0378006
2025-11-24MNKD5.140.170.0458631
2025-11-25MNKD5.370.170.9359317
2025-11-26MNKD5.390.170.0659503
2025-12-01MNKD5.430.170.1659707
2025-12-02MNKD5.590.170.1659896
2025-12-03MNKD5.580.160.6760381
2025-12-04MNKD5.720.170.1061695
2025-12-05MNKD5.680.160.0262271
2025-12-08MNKD5.640.160.0262262
2025-12-09MNKD5.780.160.0362902
2025-12-10MNKD5.850.160.1863267
2025-12-11MNKD5.810.160.0663460
2025-12-12MNKD5.950.160.2565305
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13MNKD5.08- - 0.19
2025-11-14MNKD5.07- - 0.19
2025-11-17MNKD4.97- - 0.19
2025-11-18MNKD5.05- - 0.19
2025-11-19MNKD5.00- - 0.19
2025-11-20MNKD4.99- - 0.19
2025-11-21MNKD5.04- - 0.19
2025-11-24MNKD5.13- - 0.19
2025-11-25MNKD5.36- - 0.19
2025-11-26MNKD5.39- - 0.19
2025-12-01MNKD5.44- - 0.19
2025-12-02MNKD5.59- - 0.19
2025-12-03MNKD5.59- - 0.19
2025-12-04MNKD5.72- - 0.19
2025-12-05MNKD5.68- - 0.19
2025-12-08MNKD5.63- - 0.19
2025-12-09MNKD5.77- - 0.19
2025-12-10MNKD5.85- - 0.19
2025-12-11MNKD5.81- - 0.19
2025-12-12MNKD5.95- - 0.19
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13MNKD-3.51-2.337.72
2025-11-14MNKD-3.51-2.337.71
2025-11-17MNKD-2.54-4.367.71
2025-11-18MNKD-2.54-4.367.71
2025-11-19MNKD-2.54-4.367.71
2025-11-20MNKD-2.54-4.367.71
2025-11-21MNKD-2.38-4.367.72
2025-11-24MNKD-2.311.007.72
2025-11-25MNKD-2.311.007.72
2025-11-26MNKD-2.311.007.36
2025-12-01MNKD-2.311.047.36
2025-12-02MNKD-2.311.047.36
2025-12-03MNKD-2.311.047.36
2025-12-04MNKD-2.311.047.36
2025-12-05MNKD-4.951.047.36
2025-12-08MNKD-4.950.967.36
2025-12-09MNKD-4.950.967.36
2025-12-10MNKD-4.950.967.41
2025-12-11MNKD-4.300.967.41
2025-12-12MNKD-4.300.967.41
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="MNKD" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

0.03

Avg. EPS Est. Current Quarter

0.03

Avg. EPS Est. Next Quarter

0.07

Insider Transactions

-4.3

Institutional Transactions

0.96

Beta

0.81

Average Sales Estimate Current Quarter

100

Average Sales Estimate Next Quarter

110

Fair Value

5.08

Quality Score

86

Growth Score

68

Sentiment Score

57

Actual DrawDown %

22

Max Drawdown 5-Year %

-57.3

Target Price

9.61

P/E

62.99

Forward P/E

49.5

PEG

1.39

P/S

5.81

P/B

P/Free Cash Flow

42.68

EPS

0.09

Average EPS Est. Cur. Y​

0.19

EPS Next Y. (Est.)

0.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.32

Relative Volume

0.85

Return on Equity vs Sector %

-92.5

Return on Equity vs Industry %

-77.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”MNKD” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MNKD” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MNKD” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MNKD” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MNKD” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MNKD” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MNKD” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
MannKind Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 403
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
stock quote shares MNKD – MannKind Corporation Stock Price stock today
news today MNKD – MannKind Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch MNKD – MannKind Corporation yahoo finance google finance
stock history MNKD – MannKind Corporation invest stock market
stock prices MNKD premarket after hours
ticker MNKD fair value insiders trading